Xencor, Inc. (Nasdaq: XNCR), a clinical-stage biopharmaceutical company focused on developing engineered antibodies for treating cancer and other serious conditions, has announced the launch of an underwritten public offering of its common stock. Certain investors may choose to purchase pre-funded warrants instead of common stock. Additionally, Xencor plans to grant underwriters a 30-day option to buy up to 15% more shares of common stock, including those underlying pre-funded warrants, at the offering price minus underwriting discounts and commissions. All shares and pre-funded warrants in this offering will be sold by Xencor.
The completion, size, and terms of the offering are subject to market conditions, and there is no guarantee of the offering’s success.
Leerink Partners, Raymond James, and RBC Capital Markets will serve as joint book-running managers, with Wedbush PacGrow acting as co-manager.
Proceeds from the offering are expected to fund general corporate purposes, including research and development, capital expenditures, working capital, and administrative expenses.
The offering will be made through an automatic shelf registration statement previously filed with the SEC on February 27, 2023 (File No. 333-270030). The sale will be conducted through a prospectus and accompanying prospectus supplement. Once available, the preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and accessible on their website at www.sec.gov. Copies can also be obtained by contacting Leerink Partners, Raymond James, or RBC Capital Markets through the provided contact details.
This press release does not constitute an offer to sell or solicit an offer to buy these securities, nor shall any such sale occur in a state or jurisdiction where it would be unlawful prior to proper registration.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor’s XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor’s XmAb engineering technology enables small changes to a proteins structure that result in new mechanisms of therapeutic action.
